SCHEMBL15074586

SCHEMBL15074586

CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B1OC(=O)CC(CC(=O)O)(C(=O)O)O1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMB5 P28074 17/20 0.59
▸ PSMB1 P20618 11/20 0.55
▸ PSMB2 P49721 10/20 0.55
▸ PSMB8 P28062 9/20 0.55
▸ PSMB9 P28065 9/20 0.55
▸ PSMB6 P28072 9/20 0.55
▸ PSMB10 P40306 9/20 0.55
▸ LONP1 P36776 8/20 0.55
▸ PSMB11 A5LHX3 8/20 0.55
▸ PSMA7 O14818 8/20 0.55
▸ PSMA1 P25786 8/20 0.55
▸ PSMA2 P25787 8/20 0.55
▸ PSMA3 P25788 8/20 0.55
▸ PSMA4 P25789 8/20 0.55
▸ PSMA5 P28066 8/20 0.55
▸ PSMB4 P28070 8/20 0.55
▸ PSMB3 P49720 8/20 0.55
▸ PSMA6 P60900 8/20 0.55
▸ PSMA8 Q8TAA3 8/20 0.55
▸ PSMB7 Q99436 8/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20408480 1.00 PSMB5 (0.59) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL18316250 0.94 PSMB5 (0.60) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL21194201 0.94 PSMB5 (0.57) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL21210534 0.94 PSMB5 (0.57) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL21194044 0.94 PSMB5 (0.57) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL21194105 0.94 PSMB5 (0.57) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL21194157 0.94 PSMB5 (0.57) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL21194079 0.94 PSMB5 (0.57) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL21194058 0.94 PSMB5 (0.57) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL21194160 0.94 PSMB5 (0.57) PSMB5PSMB1PSMB2PSMB8PSMB9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265111-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-08-24 — — US disclosed
US-11325942-B2 Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis BEIJING ARTIVILA BIOPHARMA CO. LTD. (CN) 2022-05-10 — — US disclosed
US-20220009948-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-01-13 — — US disclosed
US-20210198289-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-07-01 — — US disclosed
US-20210155658-A1 CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) 2021-05-27 — — US disclosed
US-20200392164-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-12-17 — — US disclosed
US-20200181176-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-06-11 — — US disclosed
US-10604538-B2 Boronate ester compounds and pharmaceutical compositions thereof MILLENIUM PHARMACEUTICALS, INC. (US) 2020-03-31 — — US disclosed
EP-3536693-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF Millennium Pharmaceuticals, Inc. (US) 2019-09-11 — — EP disclosed
US-20190263839-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-29 — — US disclosed
US-20160368945-A1 CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) 2016-12-22 — — US disclosed
US-20160031913-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-04 — — US disclosed
US-9175017-B2 Boronate ester compounds and pharmaceutical compositions thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-03 — — US disclosed
US-9175018-B2 Boronate ester compounds and pharmaceutical compositions thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-03 — — US disclosed
US-20150307523-A9 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-10-29 — — US disclosed
US-20140349966-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MILLENNIUM PHARM INC (US) 2014-11-27 — — US disclosed
US-20140343314-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-11-20 — — US disclosed
US-8859504-B2 Boronate ester compounds and pharmaceutical compositions thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 — — US disclosed
US-20140018301-A9 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-01-16 — — US disclosed
US-20130165390-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018301-A9 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PSMB5, PSMB11, PSMB3 PSMB5 1/4885PSMB1 13/4885PSMB2 23/4885
US-20140349966-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PSMB5, PSMB11, PSMB3 PSMB5 1/4885PSMB1 13/4885PSMB2 23/4885
US-20160368945-A1 CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS TBCA, BCL3, BCL6 PSMB5 1303/4885PSMB1 1087/4885PSMB2 1445/4885
US-20210198289-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PSMB5, PSMB11, PSMB3 PSMB5 1/4885PSMB1 13/4885PSMB2 23/4885
US-20210155658-A1 CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS TBCA, BCL3, BCL6 PSMB5 1303/4885PSMB1 1087/4885PSMB2 1445/4885
US-20150307523-A9 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PSMB5, PSMB11, PSMB3 PSMB5 1/4885PSMB1 13/4885PSMB2 23/4885
US-20160031913-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PSMB5, PSMB11, PSMB3 PSMB5 1/4885PSMB1 13/4885PSMB2 23/4885
US-20190263839-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PSMB5, PSMB11, PSMB3 PSMB5 1/4885PSMB1 13/4885PSMB2 23/4885
US-20230265111-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PSMB5, PSMB11, PSMB3 PSMB5 1/4885PSMB1 13/4885PSMB2 23/4885
US-10604538-B2 Boronate ester compounds and pharmaceutical compositions thereof PSMB5, PSMB11, PSMB3 PSMB5 1/4885PSMB1 13/4885PSMB2 23/4885
US-20220009948-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PSMB5, PSMB11, PSMB3 PSMB5 1/4885PSMB1 13/4885PSMB2 23/4885
US-20140343314-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PSMB5, PSMB11, PSMB3 PSMB5 1/4885PSMB1 13/4885PSMB2 23/4885
US-11325942-B2 Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis TBCA, BCL3, BCL6 PSMB5 1303/4885PSMB1 1087/4885PSMB2 1445/4885
US-20130165390-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PSMB5, PSMB11, PSMB3 PSMB5 1/4885PSMB1 13/4885PSMB2 23/4885
US-20200392164-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PSMB5, PSMB11, PSMB3 PSMB5 1/4885PSMB1 13/4885PSMB2 23/4885
US-20200181176-A1 BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PSMB5, PSMB11, PSMB3 PSMB5 1/4885PSMB1 13/4885PSMB2 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback